What a turbulent week on the stock market, I had to buy more 😅 How are things looking for you?

$KLAC (+0,46 %)
$ADBE (+1,44 %)
$SIKA (-2,18 %)
$HOLN (-0,73 %)
$MBG (-0,07 %)
$CVX (+0,4 %)
$MRNA (-1,12 %)

NASDAQ 100

These stocks will be added to the index:

-Palantir
$PLTR (+6,35 %)

-MicroStrategy
$MSTR (+8,98 %)

-Axon
$AXON (+1,43 %)

These stocks are excluded from the index:

-Super Micro
$SMCI (+1,96 %)

-Moderna
$MRNA (-1,12 %)

-Illumina
$ILMN (+0,9 %)

NASDAQ 100: $PLTR (+6,35 %) and $MSTR (+8,98 %) rise $SMCI must go

The US tech stock index NASDAQ is being shaken up. MicroStrategy and Palantir, among others, have opened a new chapter in their stock market history.

- Rebalancing of the NASDAQ 100 takes place

- Palantir and MicroStrategy celebrate inclusion in the NASDAQ 100

- Price gains ahead

The NASDA100 index lists the largest 100 companies from the tech stocks index that are not NASDAQ Composite that do not come from the financial sector. In addition to market capitalization, a strong daily trading volume is also decisive for inclusion in the index. The conditions were met by two stock corporations that were among the biggest investor favorites in 2024.

MicroStrategy and Palantir make it into the index

As the NASDAQ Stock Exchange announced on Friday after the close of trading, software companies MicroStrategy and Palantir have been included in the annual index review. $MSTR (+8,98 %) and $PLTR (+6,35 %) new members to the renowned stock market index. The adjustments will be implemented from December 23, i.e. one day before Christmas Eve.

It had already become apparent in the last few days that both $PLTR (+6,35 %) as well as $MSTR (+8,98 %) would make the leap into the NASDAQ 100 index. AI profiteer $PLTR (+6,35 %) had topped the list of the largest NASDAQ companies by market capitalization that are not listed in the 100 index by a wide margin. $MSTR (+8,98 %) also clearly outperformed most of the companies in question in terms of market capitalization.

Further share price gains ahead?

In the year to date, Palantir shares have already risen by well over 340%, while the largest shareholder at company level, MicroStrategy, has even seen an increase of around 540%. $BTC (-2,05 %) -MicroStrategy, the largest shareholder at company level, has even risen by around 540 percent.

The inclusion in the index that has now been announced could further boost the share prices of the companies, because unlike the NASDAQ Composite, there is greater visibility in the more elite NASDAQ-100 stock market segment. The redesign of the index is also forcing ETF and fund providers to update their products and to Aktienkaufto replicate the new index. A look at the history also shows that this is regularly reflected in higher share prices: between 2014 and 2023, 85 companies were included in the NASDAQ 100, and their share prices rose by an average of 17% in the 12-month period following their inclusion, writes "The Motley Fool" with a view to possible share price potential.

Other index movers and shakers

Besides $PLTR (+6,35 %) and $MSTR (+8,98 %) have also $AXON (+1,43 %) made it into the NASDAQ 100 index. Meanwhile, the criteria for remaining in the index were no longer met by $ILMN (+0,9 %) , $SMCI and $MRNA (-1,12 %) .

Editorial finanzen.net

Analyst updates, 26.11.

⬆️⬆️⬆️

- ODDO BHF upgrades DEUTSCHE TELEKOM from Neutral to Outperform. Target price EUR 35. $DTE (-0,92 %)

- BARCLAYS raises the target price for AIRBUS from EUR 165 to EUR 166. Overweight. $AIR (-0,84 %)

- BARCLAYS raises the target price for MTU from EUR 340 to EUR 356. Equal-Weight. $MTX (-0,47 %)

- DEUTSCHE BANK RESEARCH raises the target price for ANGLO AMERICAN from GBP 27 to GBP 29. Buy. $AAUKF

- UBS raises the target price for ZURICH from CHF 475 to CHF 532. Neutral. $ZURN (-0,89 %)

⬇️⬇️⬇️

- JPMORGAN lowers the price target for BIONTECH from USD 124 to USD 122. Neutral. $BNTX (+0,93 %)

- JPMORGAN lowers the price target for MODERNA from USD 59 to USD 45. Underweight. $MRNA (-1,12 %)

- UBS lowers the target price for AIR LIQUIDE from EUR 200 to EUR 195. Buy. $AI (-0,22 %)

- METZLER lowers the price target for ABO ENERGY from EUR 113 to EUR 96. Buy. $AB9 (-0,28 %)

- DEUTSCHE BANK RESEARCH lowers the target price for AIR FRANCE-KLM from EUR 10 to EUR 8.50. Hold. $AF

- UBS lowers the price target for UNITED INTERNET from EUR 24 to EUR 23. Buy. $UTDI (-1,53 %)

$MRNA (-1,12 %) I got in at just under € 35. See medium-term recovery and prospects

⬆️⬆️⬆️

- UBS raises its price target for NVIDIA from USD 150 to USD 185. Buy. $NVDA (+2,01 %)

- METZLER raises the price target for MUNICH RE from EUR 535 to EUR 543. Buy. $MUV2 (-1,1 %)

- GOLDMAN lowers the target price for NOVO NORDISK from DKK 1040 to DKK 1025. Buy. $NOVO B (-17,74 %)

- GOLDMAN upgrades MTU from Neutral to Buy and raises target price from EUR 276 to EUR 400. $MTX (-0,47 %)

- GOLDMAN upgrades BASF from Neutral to Buy and raises target price from EUR 45 to EUR 53. $BAS (-0,12 %)

- DEUTSCHE BANK RESEARCH raises the price target for FRESENIUS SE from EUR 42 to EUR 44. Buy. $FRE (-0,84 %)

- DEUTSCHE BANK RESEARCH raises the price target for EMBRACER from SEK 24 to SEK 28. Hold. $TH9A

- DEUTSCHE BANK RESEARCH raises the price target for AMADEUS IT from EUR 62 to EUR 65. Hold. $AMS (+1,89 %)

- DEUTSCHE BANK RESEARCH raises the price target for NEMETSCHEK from EUR 85 to EUR 100. Hold. $NEM (+1,42 %)

- WARBURG RESEARCH raises the price target for DÜRR from EUR 32 to EUR 33. Buy. $DURYY

- HAUCK AUFHÄUSER IB upgrades CANCOM from Hold to Buy. Target price EUR 32. $COK (+0,99 %)

- ODDO BHF upgrades GENERALI to Neutral. Target price EUR 26.10. $G (-0,26 %)

- METZLER raises the price target for HEIDELBERG MATERIALS from EUR 131 to EUR 138. Buy. $HEI (-0,69 %)

- BERENBERG raises the price target for FLATEXDEGIRO from EUR 16 to EUR 18. Buy. $FTK (-0,34 %)

- BERENBERG raises the price target for FREENET from EUR 29 to EUR 32. Buy. $FNTN (-1,23 %)

- JPMORGAN raises the target price for HEIDELBERG MATERIALS from EUR 108 to EUR 149. Overweight. $HEI (-0,69 %)

⬇️⬇️⬇️

- UBS lowers the price target for MUNICH RE from EUR 560 to EUR 540. Buy. $MUV2 (-1,1 %)

- ODDO BHF downgrades MODERNA to Outperform. Target price USD 86. $MRNA (-1,12 %)

- UBS downgrades VALE from Buy to Neutral and lowers target price from USD 14 to USD 11.50. $VALE (+0,47 %)

- DZ BANK lowers target price for DEUTZ from EUR 6.80 to EUR 5.80. Buy. $DEZ (-1,18 %)

- DZ BANK lowers the price target for BECHTLE from EUR 51 to EUR 45. Buy. $BC8 (+0,82 %)

- BERENBERG lowers the target price for ESTEE LAUDER from USD 87 to USD 76. Hold. $EL (-0,42 %)

- RBC lowers the target price for ASOS from GBP 4.60 to GBP 4. Sector Perform. $ASC (-0,95 %)

- RBC lowers the price target for EVOTEC from EUR 12 to EUR 11.60. Outperform. $EVT (+1,24 %)

- RBC lowers the price target for VESTAS from DKK 222 to DKK 156. Outperform. $VWS (-2,71 %)

- BERENBERG lowers the price target for SUSS MICROTEC from EUR 80 to EUR 75. Buy. $SMHN (+0,76 %)

- JEFFERIES downgrades NEL from Hold to Underperform and lowers target price from NOK 5.50 to NOK 3. $NEL (-0,43 %)

- RBC lowers the price target for BMW from EUR 81 to EUR 80. Sector Perform. $BMW (+0,87 %)

- JEFFERIES lowers the price target for KNAUS TABBERT from EUR 26 to EUR 20. Hold. $KTA (+0,16 %)

Moderna Q32024 $MRNA (-1,12 %)

Financial results

• Revenue: Total sales in the third quarter of 2024 amounted to 1.9 billion dollars, a slight increase compared to 1.8 billion dollars in the third quarter of 2023. Product sales totaled 2.2 billion dollars in the first nine months.
• Net profit: For the third quarter of 2024, the company reported a net profit of 13 million dollars, compared to a net loss of 3.6 billion dollars in the third quarter of 2023.
• Earnings per share (EPS): EPS was $0.03 in the third quarter of 2024, compared to a loss per share of $9.53 in the same period last year.

Balance sheet overview

• Total assets: As of September 30, 2024, total assets were $15.8 billion, a decrease from $18.4 billion at the end of 2023.
• Total liabilities: Total liabilities amounted to 3.9 billion dollars, compared to 4.6 billion dollars at the end of 2023.
• Shareholders' equity: Shareholders' equity decreased to $11.9 billion from $13.9 billion at the end of 2023.

Details of the income statement

• Cost of sales: Cost of sales amounted to 514 million dollars in the third quarter of 2024, significantly lower than the 2.2 billion dollars in the third quarter of 2023, mainly due to lower inventory write-offs and unused production capacity.
• Research and development costs: R&D costs decreased by 2% to 1.1 billion dollars in the third quarter of 2024.
• Selling, general and administrative expenses: These expenses decreased by 36% to 281 million dollars in the third quarter of 2024.

Cash flow overview

• Net cash used in operating activities: 3.8 billion dollars for the nine months ended September 30, 2024.
• Net cash inflow from investing activities: 2.5 billion dollars for the nine months ended September 30, 2024.
• Net cash used in financing activities: $146 million for the nine months ended September 30, 2024.

Key figures and profitability metrics

• Cost of sales as a percentage of net product sales: 28% in the third quarter of 2024, a significant decrease from 128% in the third quarter of 2023.

Segment information

• Sales from COVID-19 vaccines: USD 1.8 billion in the third quarter of 2024, of which USD 1.2 billion in the USA and USD 0.6 billion internationally.
• Sales from RSV vaccines: 10 million dollars in the third quarter of 2024.

Competitive position

Moderna holds a 40% market share in the US retail market for COVID-19 vaccines.

Forecasts and management comments

• Expected product sales 2024: Forecast confirmed, between 3.0 and 3.5 billion dollars.
• R&D expenditure: Expected to be between 4.6 and 4.7 billion dollars in 2024.

Opportunities and risks

• Opportunities: Expansion of the vaccine portfolio, including RSV and influenza vaccines.
• Risks: Lower than expected sales of RSV vaccines due to delayed approval.

Positive aspects

• Increase in total sales and net profit.
• Significant reduction in cost of sales.
• Successful launch of updated COVID-19 and RSV vaccines.
• Expansion of the management team to strengthen the company management.
• Solid liquidity situation with 9.2 billion dollars in cash and investments.

Negative aspects

• Decrease in total assets and equity.
• Lower than expected sales of RSV vaccines.
• Continued negative operating cash flow.
• Decline in international COVID-19 vaccine sales.
• Expected increase in capital expenditure for 2024.